Neumora Therapeutics, Inc. (NMRA)

Market Cap	414.58M
Revenue (ttm)	n/a
Net Income (ttm)	-236.30M
Shares Out	161.95M
EPS (ttm)	-1.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,214,668
Open	2.500
Previous Close	2.580
Day's Range	2.400 - 2.635
52-Week Range	0.611 - 14.090
Beta	3.03
Analysts	Buy
Price Target	7.43 (+190.23%)
Earnings Date	Nov 6, 2025

About NMRA

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 15, 2023
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: NMRA
• Website: https://www.neumoratx.com

Analyst Summary

According to 8 analysts, the average rating for NMRA stock is "Buy." The 12-month stock price target is $7.43, which is an increase of 190.23% from the latest price.

Price Target

$7.43

(190.23% upside)

Analyst Consensus: Buy